Takeda Announces New U.S. Leadership ( Proposed appointments effective...)

Takeda Announces New U.S. Leadership

Date:3/19/2008

Proposed appointments effective at conclusion of TAP transaction

DEERFIELD, Ill., March 19 /PRNewswire/ -- Takeda Pharmaceuticals North America, Inc. today announced proposed new leadership for Takeda America Holdings, Inc. (TAH), Takeda Pharmaceuticals North America, Inc. (TPNA) and Takeda Global Research & Development Center, Inc. (TGRD) following an earlier announcement related to Takeda's plans to conclude its joint venture in the United States, TAP Pharmaceutical Products Inc. (TAP).

Effective at the close of the TAP transaction, Takeda Pharmaceuticals North America, Inc. and Takeda Global Research & Development Center, Inc. will report to Takeda America Holdings, Inc. Alan MacKenzie, the current president of TAP and a former president of Takeda Pharmaceuticals North America, Inc. has been named executive vice president of Takeda America Holdings.

MacKenzie will also serve as CEO of Takeda Pharmaceuticals North America, Inc. in addition to his role as executive vice president of Takeda America Holdings.

Mark Booth, current president of Takeda Pharmaceuticals North America, Inc., will continue to lead the company until the TAP transaction is closed and has agreed to continue on with the company for some period thereafter to support integration activities.

Reporting to MacKenzie as president of Takeda Global Research & Development Center, Inc. will be Nancy Joseph-Ridge, M.D., currently TAP's vice president of research and development. Dr. Joseph-Ridge will also assume her position effective the close of the TAP transaction.

"I have great confidence in Takeda's proposed new leadership for the United States, an important market for Takeda's global growth plans," said Yasuchika Hasegawa, president, Takeda Pharmaceutical Company Limited. "Alan MacKenzie not only helped launch both TPNA and its first product, Actos, he has been instrumental in helping create success at Takeda companies for more than 22 years. Dr. Nan
'/>"/>

0

GOOD

Page: 1 2
Related medicine news :

1. Takeda submits new drug application for alogliptin (syr-322) in the US
2. Chemizon Announces Research Collaboration Expansion With Takeda
3. Takeda Statement on ACTOS(R) (Pioglitazone HCl) Meta-Analysis Published in the Journal of the American Medical Association
4. Takeda statement on ACTOS meta-analysis published in the Journal of the American Medical Association
5. QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes
6. Galderma Announces HSR Clearance for Its Proposal to Acquire CollaGenex Pharmaceuticals
7. The Pennsylvania Breast Cancer Coalition Announces Event at the University of Pennsylvania Hospital to Celebrate the 2008 Income Tax Check-Off Campaign
8. Law Offices of Howard G. Smith Announces Class Action Lawsuit Against Vertex Pharmaceuticals Incorporated
9. PRA International Announces New Office Opening in Mumbai
10. Cardiums InnerCool Therapies Unit Announces Australian Distribution Agreement for CoolBlue and Rapid Blue Systems
11. Varian Announces Global Clinical Council to Develop RapidArc(TM) Cancer Treatments

Post Your Comments:

Takeda Announces New U.S. Leadership( Proposed appointments effective...),Health